ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

Xie, Zeyu; Hu, Jia; Gu, Hangye; Li, Mengting; Chen, Jisheng*广东药学院; 1
Frontiers in Endocrinology2023-8-28DOI: 10.3389/fendo.2023.1244432
1被引24阅读
引用收藏
分享

摘要

PurposeThis study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2 diabetes and to provide evidence-based support and reference for the selection of clinical treatment.MethodsThree databases (PubMed, Embase, and Cochrane Library) were searched from their respective inception until September 30, 2022. Only randomized controlled trials comparing the efficacy and safety of GLP-1RAs for treating type 2 diabetes (T2D) were included. The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide.Results34 RCTs with 10 GLP-1RAs and 12993 patients were included in the Network Meta-Analysis (NMA). According to the NMA, tirzepatide 15 mg, semaglutide 1.0 mg, PEX168-200 & mu;g, oral semaglutide 14 and dulaglutide 1.5 mg reduced HbA1c by -2.23%, -1.57%, -1.12%, -1.10%, -1.09% and body weight by -11.33 kg, -5.99 kg, +0.40 kg, -3.95 kg, -1.87 kg, respectively. There was no significant difference in the rate of adverse events for tirzepatide 15 mg, oral-semaglutide 14 mg, and semaglutide 1.0 mg. PEX168-200 & mu;g, tirzepatide 15mg, and oral semaglutide 14mg had Surface Under the Cumulative Ranking (SUCRA) values greater than placebo, and only tirzepatide 15mg and oral semaglutide 14mg were significantly different from placebo in the rate of serious adverse events. All GLP-1RA did not lead to increased incidence of hypoglycemia. Albiglutide 30mg and semaglutide 1.0mg significantly differed from placebo in Adverse Event (AE) withdrawal. Finally, the sensitivity analysis and publication bias analysis results indicate that the study results are reliable.ConclusionThis study's results showed that GLP-1RAs were effective in lowering HbA1c and reducing body weight without increased incidence of hypoglycemic reactions. In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.

学科与关键词

关键词
glucagon-like peptide-1 receptor agonistssafetyefficacysystematic reviewrandomized controlled trialstype 2 diabetes
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2023-08-28
卷期
第 14 卷
页码
1244432
DOI
10.3389/fendo.2023.1244432
成果收录
SCIE
资助标注
National Key Specialty Construction Project (Clinical Pharmacy); High-level Clinical Key Specialty of Guangdong Province; Central Finance Subsidy Fund [Z155080000004]; Guangzhou Minsheng Science and Technology Research Program Project [201803010096]

作者

  • X

    Xie, Zeyu (第一作者)

    1 · guangdong pharmaceut univ

  • H

    Hu, Jia

    1 · guangdong pharmaceut univ

查看全部 5 位作者收起作者
  • G

    Gu, Hangye

    1 · guangdong pharmaceut univ

  • L

    Li, Mengting

    1 · guangdong pharmaceut univ

  • C

    Chen, Jisheng (通讯)

    1 · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417